Skip to main content

Company FilingsMore Search Options

SEC Emblem
U.S. Securities and Exchange Commission
q
  • About
    • What We Do
    • Commissioners
    • Securities Laws
    • Reports and Publications
    • Careers
    • Contact
  • Divisions & Offices
    • Corporation Finance
    • Enforcement
    • Investment Management
    • Economic and Risk Analysis
    • Trading and Markets
    • Office of Administrative Law Judges
    • Office of Compliance Inspections and Examinations
    • Regional Offices
    • All Divisions and Offices
  • Enforcement
    • Litigation Releases
    • Administrative Proceedings
    • Opinions and Adjudicatory Orders
    • Accounting and Auditing
    • Trading Suspensions
    • How Investigations Work
    • Receiverships
    • Information for Harmed Investors
  • Regulation
    • Rulemaking Index
    • Proposed Rules
    • Final Rules
    • Interim Final Temporary Rules
    • Other Orders and Notices
    • Self-Regulatory Organizations
    • Staff Interpretations
  • Education
    • Investor.gov
    • Five Questions to Ask Before You Invest
    • About Investment Professionals
    • Check Your Investment Professional
    • Investing Tools and Calculators
    • Investment Products
    • Understanding Fees
    • Investor Alerts and Bulletins
    • Glossary
  • Filings
    • EDGAR – Search & Access
    • EDGAR – Information for Filers
    • Company Filing Search
    • How to Search EDGAR
    • Requesting Public Documents
    • Forms List
    • About EDGAR
  • News
    • Press Releases
    • Public Statements
    • Speeches
    • Testimony
    • Spotlight Topics
    • What's New
    • Upcoming Events
    • Webcasts
    • SEC in the News
    • SEC Videos
    • Media Gallery

User account menu

  • Log in
  • U.S. Securities and Exchange Commission
    • Divisions & Offices
    • Enforcement
    • Regulation
    • Education
    • Filings
    • Newsroom
  • Newsroom
    • Press Releases
    • Public Statements
    • Speehes
    • Testimony
  • RSS Feeds
    • Press Releases
    • Public Statements
    • Speeches
    • Testimony
  • Social Media
    • @SEC_News
    • SEC Channel
    • SEC Photostream
  • ABOUT THE SEC
  • Commissioners
  • Contact
  • Data
  • Divisions and Offices
  • Regional Offices
  • Division and Office Directors
  • Forms
  • Privacy and Security
  • Reports and Publications
  • Securities Laws
  • Upcoming Events
  • What We Do

Other

Orexigen Therapeutics, Inc. (Exhibit 10.25 to 10-Q)

Jan. 31, 2018

Downloads

pdf
18-01831-E.pdf
Modified: Jan. 31, 2018

STAY CONNECTED
1 Twitter 2 Facebook 3RSS 4YouTube
5 Flickr 6LinkedIn 7 Pinterest 8 Email Updates

Footer menu

  • Accessibility
  • Budget & Performance
  • Careers
  • Contact
  • Contracts
  • Data
  • FOIA
  • Inspector General
  • Investor.gov
  • No FEAR Act & EEO Data
  • Ombudsman
  • Plain Writing
  • Privacy
  • Related Sites
  • Site Map
  • USA.gov
  • Votes
  • Whistleblower Protection
Return to Top